Document is current
Any future updates will be listed below
-
Authors
van Doremalen, Neeltje https://orcid.org/0000-0003-4368-6359
Schulz, Jonathan E.
Adney, Danielle R. https://orcid.org/0000-0002-1046-850X
Saturday, Taylor A.
Fischer, Robert J. https://orcid.org/0000-0002-1816-472X
Yinda, Claude Kwe
Thakur, Nazia https://orcid.org/0000-0002-4450-5911
Newman, Joseph https://orcid.org/0000-0003-0717-8672
Ulaszewska, Marta
Belij-Rammerstorfer, Sandra
Saturday, Greg https://orcid.org/0000-0002-0803-6177
Spencer, Alexandra J. https://orcid.org/0000-0001-7958-6961
Bailey, Dalan https://orcid.org/0000-0002-5640-2266
Russell, Colin A. https://orcid.org/0000-0002-2113-162X
Gilbert, Sarah C. https://orcid.org/0000-0002-6823-9750
Lambe, Teresa
Munster, Vincent J. https://orcid.org/0000-0002-2288-3196
-
Funding
Funding for this research was provided by:
Division of Intramural Research, National Institute of Allergy and Infectious Diseases (1ZIAAI001179-01)
- License Information
-
More Information
Article History
Received: 19 February 2022
Accepted: 22 July 2022
First Online: 8 August 2022
Competing interests
: S.C.G. is a co-founder and stock-holder of Vaccitech and named as an inventor on a patent covering the use of ChAdOx1-vector-based vaccines and a patent application covering a SARS-CoV-2 (nCoV-19) vaccine (UK patent application no. 2003670.3). T.L. is named as an inventor on a patent application covering a SARS-CoV-2 (nCoV-19) vaccine (UK patent application no. 2003670.3). The University of Oxford and Vaccitech, having joint rights in the vaccine, entered into a partnership with AstraZeneca in April 2020 for further development, large-scale manufacture and global supply of the vaccine. Equitable access to the vaccine is a key component of the partnership. Neither Oxford University nor Vaccitech will receive any royalties during the pandemic period or from any sales of the vaccine in developing countries. All other authors declare no competing interests.
